Mendoza CG, Mateo CY, Rodríguez SY, Higuera SJL, Gutiérrez VJM, Pimentel JJA

Language: Spanish
References: 22
Page: 162-166
PDF size: 131.76 Kb.

ABSTRACT

Objective: To identify the relationship between the stages of grief and therapeutic adherence in people with type 2 Diabetes Mellitus. Methods: Crosssectional and correlational study, with a sample of 179 participants aged 20 to 70 years. Data collection were carried out in health centers in three locations in the state of Oaxaca, Mexico. The Instrument to Measure Diabetic Stages of Grief and the Scale of Adherence to Medications in T2DM were used. Correlation analysis and a multiple linear regression model were performed. Results: Mean age 54.5 years (SD = 11.0), schooling was 5.3 years (SD = 3.8) and years with T2DM10.8 (SD = 7.1); 79.3% were women, 30.2% consumed alcohol, 10.1% smoked and 64.8% were overweight/obese. Therapeutic adherence was correlated with denial, negotiation and acceptance. In the linear regression model, only the stages of denial and acceptance were predictors of adherence. Conclusions: There is a significant relationship between therapeutic adherence with the stages of grief: denial and acceptance.

REFERENCES

1. International Diabetes Federation [Internet]. IDF Diabetes Atlas, 9th edn. Brussels, Belgium. Atlas de la Diabetes de la FID. 2019. [Citado 2020 Jun 16] Disponible en: http://www.idf.org/sites/default/ files/Atlas-poster-2014_ES.pdf

2. Instituto Nacional de Salud Pública (INSP), Encuesta Nacional de Salud y Nutrición. Presentación de resultados 2018 [Internet]. [Citado 2020 Jun 16]. Disponible en: https://ensanut.insp.mx/ encuestas/ensanut2018/doctos/informes/ensanut_ 2018_presentacion_resultados.pdf

3. Rojas-Martínez R, Basto-Abreu A, Aguilar-Salinas CA, Zarate-Rojas E, Villalpando S, Barrientos- Gutiérrez T. Prevalencia de diabetes por diagnóstico previo en México. Salud Pública Mex. 2018;60(3):224-32.

4. Basto-Abreu A, Barrientos-Gutiérrez T, Rojas- Martínez R, Aguilar-Salinas CA, López-Olmedo N, De la Cruz-Góngora V, Rivera-Dommarco J, Shamah-Levy T, Romero-Martínez M, Barquera S, López-Ridaura R, Hernández-Ávila M, Villalpando S. Prevalencia de diabetes y descontrol glucémico en México: resultados de la Ensanut 2016. Salud Publica Mex. 2020; 62(1):50-59.

5. Lin LK, Sun Y, Heng BH, Chew DEK, Chong PN. Medication adherence and glycemic control among newly diagnosed diabetes patients. BMJ Open Diabetes Res Care. 2017;5(1):e000429.

6. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016; 10:1299-1307.

7. Robinson DJ, Coons M, Haensel H, Vallis M, Yale JF. Diabetes and mental health. Can J Diabetes. 2018; 42: Suppl 1: S130-S41.

8. Kübbler-Ross E. On death and dying. Nueva York: Routledge, 1973.

9. Iriarte AM, Giles OA, Sandoval ME, Mendoza RD, Avilés AGP. Comparación de las prevalencias de duelo, depresión y calidad de vida asociados con la enfermedad entre pacientes con diabetes mellitus tipo 2 descontrolados y controlados. Rev Esp Med-Quir. 2013;18(1):13-18.

10. Mendoza Catalán G, Gallegos Cabrales EC, Figueroa- Perea JG. Autopsia verbal en hombres adultos con diabetes tipo 2: estudio cualitativo. Rev. Cuid. 2017: 8(3);1786-98.

11. McKenzie C, Bennert K, Kessler D, Montgomery A. The illness-disease dynamic: psychological wellbeing in type 2 diabetes: an interpretative phenomenological analysis. Qual Rep. 2016; 21(5):933-51.

12. Leitón-Espinoza ZE, Cienfuegos-Pastor MDR, Deza-Espino MD, Fajardo-Ramos E, Villanueva- Benites ME, López-González A. Impacto emocional en el camino de aprender a vivir con “la diabetes”. Rev Salud Uninorte. 2018;34(3):696-704.

13. Rodríguez-Moctezuma JR, López-Delgado ME, Ortíz-Aguirre AR, Jiménez-Luna J, López-Ocaña LR, Chacón-Sánchez J. Etapas del duelo en diabetes y control metabólico. Rev Med Inst Mex Seguro Soc. 2015;53(5):546-51.

14. Pedroza Cosío GA, Sánchez Escobar LE, Munguía Lozano S, Beltrán Lagunes L, Ferrer Álvarez JG, Medina Arreguín R, López Hernández D. Evaluación de la escala EFD-66 como herramienta para predecir la adherencia al tratamiento en pacientes con enfermedades crónicas no transmisibles. Rev Panam Salud Pública. 2017;41:e113.

15. Rezaei M, Valiee S, Tahan M, Ebtekar F, Gheshlagh RG. Barriers of medication adherence in patients with type-2 diabetes: A pilot qualitative study. Diabetes, Metab Syndr Obes Targets Ther. 2019;12:589-99.

16. International Diabetes Federation [Internet]. Bruselas, Bélgica: World health day. April 2018 [Citado 2020 Jun 16]. Disponible en: https://www. idf.org/our-network/regions-members/europe/ europe-news/95:7-april-2018-world-health-day. html

17. Mayberry LS, Gonzalez JS, Wallston KA, Kripalani S, Osborn CY. The ARMS-D out performs the SDSCA, but both are reliable, valid, and predict glycemic control. Diabetes Res Clin Pract. 2013;102(2):96-104.

18. Marcial-Ventura GA, Lugo-Radillo A, Elizarrarás- Rivas J, Contreras García CM, Elizarrarás-Cruz JD, Herrera-Lugo KG, Cruz-Jiménez FE, Escobar- Vásquez M. El duelo en pacientes con diagnóstico reciente de diabetes mellitus tipo 2 en la UMF 65 del IMSS, Oaxaca. Rev Avan C Salud Med. 2019;7(3):68-76.

19. Accinelli RA, Arias KB, Leon-Abarca JA, López LM, Saavedra JE. Frecuencia de depresión y calidad de vida en pacientes con diabetes mellitus en establecimientos de salud pública de Lima Metropolitana. Rev Colomb Psiquiatr. 2020;25(4)196- 203.

20. American Diabetes Association [Internet]. Arlington, Estados Unidos: Mental Health. [Citado 2020 Jun 16]. Disponible en: https://www.diabetes. org/diabetes/mental-health

21. Ferrara L, Singleton J, Yang K, Frederickson K, Rivera E. Grieving the loss of self: challenges in type 2 diabetes mellitus self-management. J Drl Nurs Pract. 2018:11(1); 25-34.

22. Alfian SD, Sukandar H, Lestari K, Abdulah R. Medication adherence contributes to an improved quality of life in type 2 diabetes mellitus patients: a cross-sectional Study. Diabetes Ther. 2016;7(4):755-764.